Shay Capital’s DiaMedica Therapeutics DMAC Stock Holding History

Shay Capital’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,000	Closed	-$20K	–	390
2022 Q2	$20K	Hold	10,000	–	–	﹤0.01%	391
2022 Q1	$25K	Hold	10,000	–	–	﹤0.01%	473
2021 Q4	$37K	Hold	10,000	–	–	0.01%	444
2021 Q3	$40K	Buy	+10,000	New	+$38.3K	0.01%	499

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Shay Capital's DMAC Position: Q3 2022 in Review

Shay Capital sold out of DiaMedica Therapeutics (DMAC) in Q3 2022, closing a stake of 10,000 shares — an estimated $20K sold.

Shay Capital first reported a position in DMAC in Q3 2021 and held it in 4 quarters. The position peaked at $40K in Q3 2021. 26 funds tracked by Wall St. Rank hold DMAC as of Q3 2022.

Shay Capital reported no remaining DiaMedica Therapeutics position as of Q3 2022 after selling out during the quarter.
Shay Capital sold 10,000 DiaMedica Therapeutics shares in Q3 2022, an estimated $20K.
Shay Capital first reported a position in DiaMedica Therapeutics in Q3 2021 and held it in 4 quarters.
Shay Capital's DiaMedica Therapeutics position peaked at $40K in Q3 2021.
26 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2022.

Based on Shay Capital's 13F filing for Q3 2022, filed 14 Nov 2022.